Release date: 2016-10-26
Mitral regurgitation is the most common heart valve disease. Severe mitral regurgitation can cause left ventricular enlargement, which ultimately leads to left heart failure, atrial fibrillation, and pulmonary hypertension. The prognosis of mitral regurgitation is poor, the annual mortality rate of patients with symptoms and without surgery is about 5%, and the 5-year mortality rate of patients with severe heart failure is 60%. According to statistics, the incidence of mitral regurgitation in the 65-year-old and 75-year-old population is 6.4% and 9.3%, respectively, and there are millions of patients with mitral regurgitation in China alone. With the economic and social development and the aging of the population, the incidence of mitral regurgitation has increased significantly.
For mitral regurgitation, medication can only improve the patient's symptoms, but can not prolong the patient's survival or timing of surgery. Surgical valve repair or replacement is considered the standard treatment for this disease and has been shown to relieve symptoms and prolong life. However, surgical trauma is traumatic and requires extracorporeal circulation. Many high-risk patients cannot tolerate it. Postoperative patients require a longer recovery period. Studies have shown that about 40% of patients with mitral regurgitation in the clinic are unable to tolerate surgery because of advanced age, poor cardiac function and multiple organ dysfunction, so there is no effective treatment. The development of minimally invasive, low-risk, interventional therapy devices for the treatment of mitral regurgitation has enormous social benefits and market demand. With the breakthrough development of valve interventional therapy, interventional devices for the treatment of mitral regurgitation have become domestic One of the key directions for the development of external cardiovascular devices.
According to reports, the only minimally invasive interventional device for the treatment of mitral regurgitation that has been approved for marketing and widely used in the world is Abbott's MitraClip. However, the device has not yet been officially listed in China, and the price is expensive (up to more than 200,000 RMB), so MitraClip has not been promoted in China, so that a large number of domestic mitral regurgitation patients can not get effective treatment. In addition, MitraClip contains a complex control system, the operation is very complicated, and doctors often take a long time to complete a surgery.
Academician Ge Junbo has been working on clinical research and device development for minimally invasive interventional therapy for heart valves. He has pioneered several transcatheter heart valve replacement or repair operations in China. In addition to the "valve-clamp" jointly developed by the company, the inventor, in addition to the academician Ge Junbo, also has doctors such as Pan Wenzhi, Cheng Leilei and Zhou Daxin from Zhongshan Hospital. The invention has the advantages of minimally invasive implantation, low cost, simple operation, good expected effect, and the like, and is expected to become an interventional device for treating mitral regurgitation with independent property rights, based on domestic and going global.
It is reported that the affiliated Zhongshan Hospital has formulated a series of rules and regulations in recent years. It not only realizes the systematic management of patents and other intellectual property rights within the whole hospital, but also is good at discovering new ideas and golden ideas from medical research work, and encouraging medical personnel to actively apply for patents. , achieved remarkable results.
Source: Zhongshan Hospital, Fudan University
Two-Piece Baseplate,2 Piece Colostomy Bags Chassis,Ostomy Bags Chassis,Hypoallergenic Ostomy Chassis
Wenzhou Celecare Medical Instruments Co.,Ltd , https://www.wzcelecare.com